SCHEDULE 13G/A: Long Focus Capital Group Divests Vincerx Pharma Stake, Ownership Drops Below 5%

An investment group led by Long Focus Capital Management, LLC has filed a final amendment to its Schedule 13G, indicating its beneficial ownership in Vincerx Pharma, Inc. common stock has decreased to 0% as of December 31, 2024.

Summary

• Long Focus Capital Management, LLC, Long Focus Capital Master, LTD., Condagua, LLC, John Helmers, and Glenn Helmers (collectively, the 'Reporting Persons') have filed an Amendment No. 2 to their Schedule 13G for Vincerx Pharma, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 0.00 shares of Vincerx Pharma, Inc. common stock, representing 0% of the class.
• This filing is noted as the final amendment due to the decrease in the combined ownership of the Reporting Persons below the 5% reporting threshold.
• The Reporting Persons certify that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This Schedule 13G filing is primarily a compliance disclosure regarding a change in beneficial ownership, not a performance report. The divestment of shares by the reporting group is a factual event without stated positive or negative implications for the issuer within the document itself.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Vincerx Pharma, Inc.'s operations or financial performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect." (Certification by Reporting Persons)
• "By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to LONG FOCUS CAPITAL MASTER, LTD., is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D." (Certification by Long Focus Capital Master, LTD.)

Industry Context

This filing is a standard regulatory disclosure of a change in beneficial ownership by an investment group and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The divestment by a previously significant investor group may be interpreted by other shareholders as a change in investor sentiment or strategy regarding Vincerx Pharma, Inc.

Next Steps

• This filing is noted as the final amendment, indicating that the Reporting Persons will not file further Schedule 13G amendments unless their beneficial ownership in Vincerx Pharma, Inc. common stock again exceeds the 5% threshold.

Key Dates

Keywords

Vincerx Pharma, Long Focus Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Group, Shareholding, Divestment